Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic naldemedine for opioid-induced nausea and vomiting in cancer
jRCTs031250128Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in cancer pain, Opioid-induced nausea and vomiting (OINV) and opioid-induced constipation (OIC) comparing Naldemedine arm with Placebo arm (2 arms). Primary endpoint: Complete Response on Day 5 (CR5). Started Jun 2025; status: active, not recruiting.
02
Drugs
naldemedine
03
Conditions
cancer painOpioid-induced nausea and vomiting (OINV)opioid-induced constipation (OIC)
Beyond the preview
Go deeper on jRCTs031250128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250128.